Health Care·Pharmaceuticals·$35.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.40 | N/A | -27.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.40 | N/A | -27.27% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficult market conditions impacting performance. They did not offer new guidance, indicating uncertainty about future results.
Management highlighted ongoing challenges in the market.
They expressed concerns about competitive pressures affecting pricing.
No specific guidance was provided for future quarters.
Teva Pharmaceutical's earnings report shows a significant miss on EPS, leading to an 8.24% drop in stock price. The company faces ongoing challenges in the market, particularly with pricing pressures and competition. The lack of guidance adds to investor uncertainty about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ARCELLX INC
May 8, 2023